Categories: News

ICU Deadline: Rosen Law Firm Urges SeaStar Medical Holding Corporation (ICU, ICUCW) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

NEW YORK–(BUSINESS WIRE)–Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of all purchasers of securities of SeaStar Medical Holding Corporation (NASDAQ: ICU, ICUCW) between October 31, 2022 and March 26, 2024. SeaStar describes itself as a “medical technology company developing extracorporeal therapies to reduce the consequences of excessive inflammation on vital organs.”


For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653.

The Allegations: The Rosen Law Firm is Investigating the Allegations that SeaStar Medical Holding Corporation (NASDAQ: ICU, ICUCW) Misled Investors Regarding its Business Operations.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) SeaStar and/or Legacy SeaStar had deficient compliance controls and procedures related to the Humanitarian Device Exemption (“HDE”) Application; (2) accordingly, there were deficiencies with the HDE Application, the FDA was unlikely to approve the HDE Application in its present form, and the Selective Cytopheretic Device’s (“SCD”) regulatory prospects were overstated; (3) SeaStar had downplayed the true scope and severity of deficiencies in its financial controls and procedures, while overstating defendants’ efforts to remediate the same; (4) accordingly, SeaStar had failed to properly account for the classification of certain outstanding warrants and the Prepaid Forward Agreement; (5) as a result, SeaStar was likely to restate one or more of its previously issued financial statements; (6) accordingly, SeaStar’s post-Merger business and financial prospects were overstated; and (7) as a result, SeaStar’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

What Now: You may be eligible to participate in the class action against SeaStar. Shareholders who want to serve as lead plaintiff for the class must file their motions with the court by September 6, 2024. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

About Rosen Law: Some law firms issuing releases about this matter do not actually litigate securities class actions; Rosen Law Firm does. A recognized leader in shareholder rights litigation, the attorneys and staff of Rosen Law Firm have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing. Since our inception, we have obtained over $1 billion for shareholders.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contacts

Laurence Rosen, Esq.

Phillip Kim, Esq.

The Rosen Law Firm, P.A.

275 Madison Avenue, 40th Floor

New York, NY 10016

Tel: (212) 686-1060

Toll Free: (866) 767-3653

Fax: (212) 202-3827

case@rosenlegal.com
www.rosenlegal.com

Staff

Recent Posts

NervGen Pharma Reports Q1 2025 Financial Results and Provides Operational Updates

Completed last subject, last visit in the chronic cohort, data readout targeted for early June…

49 minutes ago

Philips Future Health Index 2025 Report Highlights Significant Trust Gap in Healthcare AI Between Clinicians and Patients

AI in healthcare can address some of healthcare’s most pressing challenges, but trust barriers threaten…

3 hours ago

New DiMe Seal Sets Benchmarks for Digital Health Products

Digital Medicine Society (DiMe) and Elevance Health collaborate to evaluate and elevate digital health software…

3 hours ago

Novo Holdings appoints four new members to its Board of Directors further strengthening global perspectives and strategic capabilities

COPENHAGEN, Denmark, May 15, 2025 /PRNewswire/ -- Novo Holdings is pleased to announce the appointments…

3 hours ago

Guelph General Hospital adds digital pathology to cloud service from Sectra–enables integrated diagnostics for improved patient care

LINKÖPING, Sweden and MISSISSAUGA, ON, May 15, 2025 /PRNewswire/ -- International medical imaging IT and…

3 hours ago

Omnicell Announces New Products for Perioperative and Clinic Settings

RFID-Enabled Dispensing and Intelligent Inventory Management Software Aim to Unlock Greater Inventory Accuracy and Streamline…

15 hours ago